High-quality products
Reliable performance
Multiple biomarkers are being evaluated to guide the use of immune checkpoint inhibitors in non-small cell lung cancer (NSCLC), including staining of programmed death-ligand 1 (PD-L1) tumor cells. We can accurately quantify PD-L1 status and identify multiple mutations by using a single bronchoscopic specimen.
High-quality products
Reliable performance
Wide range of applications
For various laboratory needs
Expert support
Professional service team
Fast delivery
Global shipping